Production of chlorinated quinoid metabolites was investigated in the livers of Sprague-Dawley rats and B6C3F 1 mice following single oral administration of pentachlorophenol (PCP) (0 -40 mg/kg body weight) and in male Fischer 344 rats, following chronic ingestion of PCP at 1,000 ppm in the diet for 6 months (equivalent to 60 mg PCP/kg body weight/day). Analyses of the rates of adduction in the livers of Sprague-Dawley rats and B6C3F 1 mice suggested that the production of tetrachloro-1,2-benzosemiquinone (Cl 4 -1,2-SQ) adducts was proportionally greater at low doses of PCP (less than 4 -10 mg/kg body weight) and was 40-fold greater in rats than in mice. Production of tetrachloro-1,4-benzoquinone (Cl 4 -1,4-BQ) adducts, on the other hand, was proportionally greater at high doses of PCP [greater than 60 -230 mg/kg body weight] and was 2-to 11-fold greater in mice than in rats over the entire range of dosages. A mathematical model employed these data to predict the rates of daily adduct production and steady state levels of PCP-derived quinone and semiquinone adducts in rats and mice. To evaluate predictions of the model, levels of PCP-derived adducts at steady state were investigated in the livers of male Fischer 344 rats chronically ingesting 60 mg PCP/kg body weight/day. Levels of total Cl 4 -1,4-BQ-derived adducts in liver cytosolic proteins (Cp) (22.0 nmol/g) and in liver nuclear proteins (Np) (3.07 nmol/g) were comparable to those of model predictions (15.0 and 3.02 nmol/g for Cp and Np, respectively). Overall, these results suggest that species differences in the metabolism of PCP to semiquinones and quinones were, in part, responsible for the production of liver tumors in mice but not rats in chronic bioassays.
Pentachlorophenol (PCP), a carcinogen in mice and possibly in humans, has been widely used as a biocide (WHO, 1987) . Chronic bioassays of PCP in rodents have shown the liver to be a target of toxicity and carcinogenicity (McConnell et al., 1991; NTP, 1997; Umemera et al., 1996; Villena et al., 1992) . However, species and dose effects were apparent. Ingestion of PCP induced liver tumors in B6C3F 1 mice (17-118 mg/kg body weight) (McConnell et al., 1991) but not in either Sprague-Dawley rats (1-30 mg/kg body weight) (Schwetz et al., 1978) or Fischer 344 rats (10 -60 mg/kg body weight) (NTP, 1997) . It is also worth noting that in the NTP two-year bioassay, PCP induced mesotheliomas (originating from the tunica vaginalis) and nasal squamous cell carcinomas in male Fischer 344 rats receiving 60 mg PCP/kg body weight in feed for the first year only (NTP, 1997) .
Metabolic activation is thought to play a role in PCP toxicity and carcinogenicity. Liver microsomal cytochrome P450s mediate the conversion of PCP to tetrachlorohydroquinone (Cl 4 HQ) and tetrachlorocatechol (Cl 4 CAT) (Ahlborg et al., 1974 (Ahlborg et al., , 1978 Jakobson et al., 1971; Renner and Hopfer, 1990; Tashiro et al., 1970; Van Ommen et al., 1986) , which are oxidized to tetrachloro-1,4-benzoquinone (Cl 4 -1,4-BQ) and tetrachloro-1,2-benzoquinone (Cl 4 -1,2-BQ), respectively, via the corresponding semiquinones (Lin et al., 1996; Renner and Hopfer, 1990; Van Ommen et al., 1988) . Direct oxidation of PCP to Cl 4 -1,4-BQ by cytochrome P450s or peroxidases has been suggested as an alternative pathway (Reitjens et al., 1997; Samokyszyn et al., 1995) . Covalent binding of PCP semiquinones and quinones with proteins and DNA has been reported in vitro (Lin et al., 1996; Van Ommen et al., 1988) and in vivo in rodents (Bodell and Pathak, 1998; La et al., 1998; Lin et al., 1997) . Previously, we reported that the nuclear dose of PCPderived quinones was greater in the livers of B6C3F 1 mice than of Sprague-Dawley rats, and we speculated that this might have played a role in the bioassay results (Lin et al., 1997) . In addition, as the administered dose of PCP was increased, we observed nonlinear production of quinone and semiquinone adducts in rat liver proteins (Lin et al., 1996) . We undertook the current investigation to determine whether similar dose-rate effects of PCP-derived adducts were observed in the livers of B6C3F 1 mice. To facilitate comparisons of quinone and semiquinone levels in different species, strains and dose regimens, a mathematical model was developed to predict the daily production of liver protein adducts associated with administration of PCP. Using the model developed with data from Sprague-Dawley rats, we compared predicted levels of PCP-derived adducts at steady state with those determined in a chronic-feeding study of male Fischer 344 rats (1000 ppm of PCP in the diet for 6 months, equivalent to 60 mg PCP/kg body weight/day) conducted by the National Toxicology Program (NTP, 1997).
MATERIALS AND METHODS
Chemicals. The purity of pentachlorophenol (99% pure, purchased from Aldrich, Milwaukee, WI) which was administered to Sprague-Dawley rats and B6C3F 1 mice in our laboratory was the same as that reported by NTP in its bioassay of Fischer 344 rats. All other chemicals used in this study were the same as those reported by Lin et al. (1997) .
Administration of PCP to Animals. For the single dose study, male B6C3F 1 mice (30 -36 g) and Sprague-Dawley rats (320 -375 g) were obtained from Charles River Breeding Laboratories. PCP was administered to the mice in this study, whereas rats had been dosed with PCP as previously described by Lin et al. (1996) . To determine the production of adducts at various doses of PCP, a single dose of PCP was administered to 5 groups of animals (4 mice or 3 rats/group) in phosphate-buffered saline (0, 5, 10, 20 , 40 mg/kg body weight) by gavage at a dosing volume of 5 mL/kg body weight. Animals were sacrificed 24 h after administration. Controls were given 10 mM phosphate-buffered saline and sacrificed 24 h after administration. Immediately after the collection of blood by cardiac puncture, livers were perfused with a 0.25 M sucrose solution (1 mL/10 g body weight), excised, washed in 0.25 M sucrose solution, and frozen at Ϫ80°C until further processing.
For the chronic study, livers were provided by the National Toxicology Program (NTP) from 10 male Fischer 344 rats, which had ingested food containing 1000 ppm of PCP for 6 months, and 10 control animals. The NTP had determined that the dietary input was equivalent to 60 mg PCP/kg body weight/day. The livers were stored at Ϫ80°C until processing.
Isolation of Liver Cytosolic Proteins (Cp) and Nuclear Proteins (Np).
Liver Cp, mouse-liver nuclei, and Np were isolated as described by Lin et al. (1996 Lin et al. ( , 1997 .
Measurement of quinone and semiquinone adducts. All cysteinyl adducts, arising from the chlorinated benzoquinones and benzosemiquinones, were assayed by the Raney nickel procedure as described by Lin et al. (1996) , using isotopically labeled, protein-bound internal standards that had been prepared from rat-liver Cp and calf-thymus histones. This assay employed Raney nickel to catalytically cleave the sulfur-bound adducts in the presence of ascorbic acid to yield various chlorinated hydroquinones and phenols. Following extraction and derivatization with heptafluorobutyrylimidazole (HFBI), the analytes were quantified by gas chromatography-mass spectrometry (GC-MS) with negative ion chemical ionization (NICI) as described below. We designate the monosubstituted cysteinyl adducts of Cl 4 -1,2-BQ, Cl 4 -1,2-SQ and Cl 4 -1,4-SQ as Cl 3 -1,2-BQ-Y, Cl 4 -1,2-SQ-Y and Cl 4 -1,4-SQ-Y, respectively, and the products of multiple reactions of Cl 4 -1,4-BQ with cysteine residues as Cl x -1,4-BQ-Y (4Ϫx) , where Y denotes a sulfhydryl group, and 0 Յ ϫ Յ 3 represents the number of chlorine atoms remaining on the aromatic nucleus.
GC-MS Analysis. All samples were analyzed by GC-MS in the NICI mode using a HP 5890 plus Series II gas chromatograph coupled to a HP 5989B MS engine. The gas chromatographic and mass spectrometric conditions were similar to those described by Lin et al. (1996 Lin et al. ( , 1997 . The limit of detection for both quinone and semiquinone adducts was estimated to be 2 pmol/g when a 10-mg portion of protein was assayed.
Development of a Mathematical Model for Production of PCP-Derived
Adducts. We previously observed in Sprague-Dawley rats that production of chlorinated quinone adducts was greater-than-proportional to PCP dose while production of chlorinated semiquinone adducts was less than proportional to PCP dose (Lin et al., 1996) . These differences in production of PCP-derived adducts may be rationalized by assuming that the adducts arise from two metabolic pathways, as illustrated in Figure 1 . Under the proposed scheme, one pathway involves direct conversion of PCP to quinones while the other proceeds via the corresponding semiquinones, which either form adducts directly or are oxidized to the quinones, which can then form adducts. We assume that the production of both quinone and semiquinone adducts follows Michaelis-Menten kinetics, at velocities V i (pmol/g protein/day) (for i ϭ q for quinone adducts, and s for semiquinone adducts), which is given by the following expression:
Here, PCP represents the single administered dose (mg/kg body weight), V max,i (pmol/g protein/day) represents the maximum rate of production of the i-th adduct, and K m,i (mg PCP/kg body weight) represents the administered dose of PCP at which the rate of production of the i-th adduct reaches one-half of V max,i . In this conceptualization of the metabolic process, V q represents the overall rate of production of quinone adducts by both the direct and the semiquinonemediated pathways. It is also assumed that any deflection from the linearity of adduct formation vs. administered dosage reflects the metabolic transformation of PCP to semiquinones and quinones via Equation 1 and is not related to differential rates of adduct elimination at different doses of PCP. For all semiquinone adducts, evidence in rats and mice indicated saturable metabolism over the whole range of administered doses (5-40 mg PCP/kg body weight). Thus, both V max,s and K m,s were estimated from nonlinear regression analysis by fitting Equation 1 to the experimental data in rats (both Cl 4 -1,2-SQ-Y and Cl 4 -1,4-SQ-Y in liver Cp and Np, derived from Lin et al., 1996) and mice (Cl 4 -1,2-SQ-Y in liver Cp only). We define R s ϭ V max,s K m,s as the pseudo-first-order rate of semiquinone-adduct production at low doses
FIG. 1.
Scheme for the metabolism of pentachlorophenol (PCP) and production of protein adducts. PCP, pentachlorophenol; Cl 4 HQ, tetrachlorohydroquinone; Cl 4 -1,4-SQ, tetrachloro-1,4-benzosemiquinone; Cl 4 -1,4-BQ, tetrachloro-1,4-benzoquinone, and the formation of protein adducts. Two metabolic pathways are assumed, i.e., one involving direct conversion of PCP to quinones and the other involving the corresponding semiquinones, which either form adducts or are oxidized to the quinones which can then form adducts. Note that the oxidation of PCP to tetrachlorocatechol (Cl 4 CAT), tetrachloro-1,2-benzosemiquinone (Cl 4 -1,2-SQ), and tetrachloro-1,2-benzoquinone (Cl 4 -1,2-BQ) also occurs but is not shown.
where PCP Ӷ K m,s . Since our experiments provided no evidence of saturation of the production of quinone adducts, we infer that the value of V q was linear within the dose range of 5-40 mg PCP/kg body weight (but not necessarily at higher doses). Guided by Figure 1 , V q represents the sum of the pseudo-first order rates of formation of quinone adducts via the direct and semiquinone-mediated pathways, minus the capacity-limited rate of formation of semiquinone adducts. As described by Tsuchiya and Levy (1972) and Ludden (1991) (with modifications), the kinetics of formation of quinone adducts can, therefore, be described by the following relationship:
where R q represents the pseudo-first-order rate of quinone-adduct production (by both pathways) and ␤ ϭ V q /V s . Values of R q and ␤ were estimated by fitting Equation 2 to the levels of quinone adducts of rat-liver Cp and Np (derived from data given in Lin et al., 1996) . From Equation 2, it follows that when PCP ӷ K m,s ,
and when PCP Ӷ K m,s ,
The first derivatives of Equations 3 and 4, with respect to PCP, represent the dose-specific rates of production of quinone adducts at high (designated R q,Hi ) and low (designated R q,Lo ) doses of PCP, respectively. That is,
and
Specifically, the high dose of PCP is defined as the dose level of PCP when (R q Ϫ ␤R s ) Ն 0.9 R q , and the low dose of PCP as PCP Յ 1 4 K m,s . The rates of quinone-adduct formation [(pmol/g)/(mg/kg body weight)/day] were estimated by substituting the estimates of R q , ␤, and R s into Equations 5 and 6.
We found that the production of semiquinone adducts in mice either was not present (Cl 4 -1,4-SQ-Y was not detected in mouse-liver Cp and Np and Cl 4 -1,2-SQ-Y was not detected in mouse-liver Np) or was trivial compared to that of quinone adducts (with ␤ Х 0.001 for Cl 4 -1,2-SQ-Y vs. Cl 3 -1,2-BQ-Y in mouse liver Cp). In either case, from Equation 2, it follows that when the quantity ␤V max,s approaches zero then
Thus, the production of quinone adducts (arising from both Cl 4 -1,2-BQ and Cl 4 -1,4-BQ) in mouse-liver Cp and Np was assumed to be proportional to the administered dosage of PCP and values of R q in mouse-liver were estimated by fitting Equation 7 to the levels of quinone adducts measured in Cp and Np.
Estimation of adduct levels at steady state. The following procedure was used to predict the average levels of PCP-derived adducts at steady state (A 60 , nmol/g) in Sprague-Dawley rats assuming chronic dosing at 60 mg PCP/kg body weight/day (the administered dose in the NTP chronic feeding study). Following Granath et al. (1992) ,
where V 60 represents the rate of production of adducts (nmol/g protein/day) at 60 mg PCP/kg body weight/day and is derived from Equations 1 and 2, and k ae (day Ϫ1 ) is the adduct-elimination rate in the initial phase. Regarding elimination of the adducts, we previously reported biphasic elimination of PCPderived adducts in liver proteins following single oral administration of PCP to Sprague-Dawley rats (at 20 mg/kg body weight), which were sacrificed at various time intervals ranging from 2-336 h (Lin et al., 1997) . Since the contribution of adduct levels in rats derived from the terminal phase (i.e., half time ϭ 5 days for liver Cp) was much less than that from the initial phase (half time ϭ 0.33-0.50 day), the initial-phase k ae was used to predict the value of A 60 . Predicted values of A 60 for all PCP-derived adducts are summarized in Tables 3 and 4 . Values of A 60 were not predicted for Cl 4 -1,4-SQ-Y in liver Np because elimination of adducts was not observed and the adduct level was low (Lin et al., 1997) .
Statistical Analysis. All data are expressed as estimated means Ϯ SEs. Since linear models were used to estimate values of R q,Hi in rats and R q in mice, the statistical comparison employed a Student's t-test assuming unequal variances (Table 2) . Two-tailed statistical significance was indicated by a p-value less than 0.05. Linear and nonlinear regression analyses and numerical iteration were performed with SlideWrite Plus (Advanced Graphics Software, Carlsbad, CA), given initial values of V max,s ϭ 100 and K m,s ϭ 10 in Equation 1 and of R q ϭ 100 and ␤ ϭ 10 in Equation 2. The coefficients of determination (r 2 ) for the least-squares regression were in the ranges of 0.812 Ͻ r 2 Ͻ 0.992 for semiquinone adducts in both rats and mice by Equation 1, 0.924 Ͻ r 2 Ͻ 1.000 for quinone adducts in rats by Equation 2, and 0.840 Ͻ r 2 Ͻ 0.975 for quinone adducts in mice by Equation 7.
RESULTS

Production of Quinone and Semiquinone Adducts in vivo in B6C3F 1 Mouse-Liver Proteins
The formation of adducts in liver proteins was investigated in B6C3F 1 mice over the range of 0 -40 mg PCP/kg body weight. Figures 2, 3 , and 4 (bottom) depict the adduct levels measured vs. PCP dose. The levels of quinone adducts of Cp were much greater than those of Np (3-100 fold). This result is in contrast to that observed in vitro where adduct levels were 2-40 fold greater in Np than Cp (Lin et al., 1997) . We suspect that this difference can be explained by the loss of accessibility of the quinone metabolites to the nuclear macromolecules in vivo. Whereas the quinones had direct access to the nuclear macromolecules in vitro (since the nuclear membrane had been disrupted by sonication), the presence of the nuclear membrane in intact cells would have diminished accessibility in vivo, given the reducing equivalents of the cytoplasm and possible membrane restrictions to mass transport. Additionally, only one semiquinone adduct, i.e., Cl 4 -1,2-SQ-Y, was observed and this adduct was found in Cp but not in Np (below the limit of detection). For both Cp and Np adducts, linear relationships were observed over the entire range of doses, except for Cl 4 -1,2-SQ-Y where less than proportional production of adducts was observed above 20 mg/kg body weight (Fig. 2,  bottom) . As observed in vitro, the levels of Cl 4 -1,4-BQ-derived adducts decreased in the order monosubstituted Ͼ trisubstituted Ͼ disubstituted in both Cp and Np.
Analyses of the Dose-Dependent Production of PCP-derived Adducts in Rat-and Mouse-liver Proteins
Referring first to the pathway leading to formation of semiquinone adducts, results are summarized in Table 1 . Estimates of K m,s were comparable for all of the semiquinone adducts that were detected in rats and mice (ranging from 17-40 mg PCP/kg body weight). In contrast, the maximal rates of production of semiquinone adducts (V max,s ) varied greatly both within and between species. For example, the values of V max,s for Cl 4 -1,2-SQ-Y in rat Cp, rat Np and mouse Cp were 634, 98.6 and 19.1 pmol/g/day, respectively. The estimates of R s ϭ V max,s /K m,s , representing linear rates of adduct production when PCP Յ 4 -10 mg/kg body weight (Յ Referring next to formation of quinone adducts, results are presented in Table 2 . Estimated values of R q for adducts derived from Cl 4 -1,4-BQ in both rats and mice followed the rank order: Comparing the linear rates of adduct production between rats (R q,Hi ) and mice (R q ), Table 2 shows that the rates were greater in mice for all of the adducts, and that the differences were statistically significant (p Ͻ 0.05) in all cases except for Cl-1,4-BQ-Y 3 in Cp. Figure  4 depicts the levels of Cl 3 -1,4-BQ-Y and Cl 4 -1,4-SQ-Y measured in rat-and mouse-liver Cp vs. PCP dose, and the lines represent the model fitted to the experimental data using either Equations 1 or 2.
Production of Quinone and Semiquinone Adducts in vivo in Fischer 344 Rat-Liver Proteins
The steady state levels of PCP-derived adducts in liver proteins were investigated in male Fischer 344 rats administered 60 mg PCP/kg body weight/day in the diet. Results of assays of adduct levels in these livers are summarized in Tables  3 and 4 . The types of adducts produced in Fischer 344 rats were comparable to those observed in Sprague-Dawley rats ( Table 2) . Levels of Cl 4 -1,4-BQ-derived adducts of Cp were generally much greater than those of Np (3-8 fold), and the levels decreased in the order: monosubstituted Ͼ trisubstituted Ͼ disubstituted in both Cp and Np. No adducts derived from Cl 4 -1,2-BQ were found and no adducts were detected in the control animals. Production of semiquinone adducts, i.e., Cl 4 -1,2-SQ-Y and Cl 4 -1,4-SQ-Y, in liver Cp and Np were also observed. For both Cp and Np the values of steady state adduct levels (A 60 ) observed in Fischer 344 rats were similar to those predicted in Sprague-Dawley rats on the basis of a single oral administration of PCP (Tables 3 and 4) .
DISCUSSION
The objective of this study was to investigate the production of chlorinated quinone and semiquinone adducts in the livers of male B6C3F 1 mice, Sprague-Dawley rats, and Fischer 344 rats. Regarding adducts of cytoplasmic and nuclear proteins of liver cells from male B6C3F 1 mice to which PCP had been administered (0 -40 mg/kg body weight), we detected both monosubstituted adducts (arising from Cl 4 -1,2-BQ and Cl 4 -1,4-BQ) and multisubstituted adducts (arising from Cl 4 -1,4-BQ). Our results indicate that the primary reactive metabolites of PCP, i.e., Cl 4 -1,2-BQ and Cl 4 -1,4-BQ, were both present in mouse livers and that the production of adducts increased proportionally with the administered dose of PCP (Figs. 2 and 3) . Additionally, for semiquinone adducts, only small amounts of Cl 4 -1,2-SQ-Y were detected in mouse-liver CP and the levels increased less than proportionally with increased doses of PCP. This is in contrast to our results in Sprague-Dawley rats where production of adducts of Cl 4 -1,4-BQ was greater than proportional to PCP dose, Cl 4 -1,2-SQ was one of the primary liver-binding species, and Cl 4 -1,2-BQ adducts were not detected (Lin et al., 1996) . These results suggest that metabolism of PCP to liver-binding intermediates differs between rats and mice.
To gauge the relative rates of adduction in rats and mice, we analyzed the dose-dependent production of adducts using both linear (mouse) and nonlinear (rat) models. As shown in Figure  1 , we postulated that quinone adducts can be generated either via the semiquinone intermediate (which can also form adducts), or via direct oxidation of PCP (current evidence supports this pathway only for the Cl 4 -1,4-BQ isomer). Since the proportion of quinone adducts arising from the two pathways in the rat depended upon the dose of PCP, we used the models to predict the daily rate of adduct formation per unit dose at Table 3. low doses (PCP Յ 4 -10 mg/kg body weight) and high doses (PCP Ն 60 -230 mg/kg body weight).
The predicted rate of production of semiquinone adducts was proportionally greater at low doses of PCP, where the linear rates of production of semiquinone adducts (R s ) were much greater in rats than in mice (see Table 1 ). Thus, at low doses of PCP, the fate of semiquinones appears to favor disproportionation to hydroquinones and quinones in rats and oxidation to quinones in mice. This seems reasonable since the P450-derived superoxide anion radical [which serves to oxidize quinols to quinones and generates hydrogen peroxide (Van Ommen et al., 1988) ] is produced to a greater extent in the mouse liver (Parke and Ioannides, 1990) .
On the other hand, the production of quinone (Cl 4 -1,4-BQ) adducts in rats appears to be proportionally greater at high doses of PCP. In this dose region, the predicted daily rate of quinone adduct production in rats (R q,Hi ) was greater than at low doses (R q,Lo ) ( Table 2 ). This indicates that the overall production of Cl 4 -1,4-BQ in the livers of rats is limited, due to the competing pathway leading to Cl 4 -1,4-SQ (Fig. 4, top) . When comparing between species, the daily rate of adduct production in mice (R q ) was greater than that observed in rats (R q,Hi ) ( Table 2) .
Taken together, these results suggest that both the types and amounts of adducts generated in rats and mice differ, particularly in the low-dose region where rats produce proportionally more semiquinone adducts and proportionally less quinone adducts than mice. It also seems clear that quinones (Cl 4 -1,2-BQ and Cl 4 -1,4-BQ) and not semiquinones are the major binding species derived from PCP metabolism in mice and that direct oxidation of PCP to quinones is greater in mice than rats. Since the rates of adduct elimination were comparable in mice and rats (Lin et al., 1997) , we therefore infer that differences in Note. Point estimates (and SEs), based upon regression analyses described in the text. V max,s is the maximum rate of production of adduct [(pmol/g)/(day)]; K m,s is the administered dose of PCP at which the rate of production of adducts reached one-half of the V max,s (mg PCP/kg body weight); R s ϭ V max,s /K m,s is the daily production of adducts per unit dose of PCP when PCP Ӷ K m,s [(pmol/g)/(mg PCP/kg body weight)/(day)]. Values of V max,s and K m,s were estimated using Equation (1) in the text; nd ϭ not detected. Note. R q is the daily production of adducts per unit dose of PCP [(pmol/g)/ (mg/kg body weight)/(day)].
TABLE 2 Estimated Daily Production of Quinone Adducts per Unit Dose of PCP (R q ) (SE) Following
a Significantly different values between R q,Hi in rats and R q in mice are designated by * (p Ͻ 0.05).
b R q,Lo was estimated using Equation 6: R q,Lo ϭ R q Ϫ ␤R s for the case where PCP Յ 10 and 4 mg/kg body weight in liver Cp and Np, respectively. c R q,Hi was estimated using Equation 5: R q,Hi ϭ R q for the case where PCP Ն 230 and 60 mg/kg body weight in liver Cp and Np, respectively.
d R q was estimated using Equation 7: V q Х R q PCP over the whole range of PCP dose.
e Not detected.
tumor formation between the two species probably reflected differences in metabolism (leading to different amounts and types of adducts) rather than differences in adduct clearance. When we investigated the formation of PCP-derived adducts in the livers of male Fischer 344 rats, chronically exposed to 60 mg PCP/kg body weight/day, we observed that both the types and relative abundances of the adducts were generally comparable to those observed in Sprague-Dawley rats following a single oral administration (Tables 3 and 4 ). For quinone adducts, no adducts derived from Cl 4 -1,2-BQ were detected, suggesting that Cl 4 -1,4-BQ is the only PCP-quinone produced in rat liver. For semiquinone adducts, levels of Cl 4 -1,2-SQ-Y were 3-to 4-fold greater than Cl 4 -1,4-SQ-Y, which is different from what had been observed in Sprague-Dawley rats where Cl 4 -1,2-SQ-Y was 15-to 60-fold greater than Cl 4 -1,4-SQ-Y (Lin et al., 1996) .
Based upon a mathematical model, describing the nonlinear production of adducts following a single oral administration of PCP to Sprague-Dawley rats, we predicted adduct levels at steady state, following chronic uptake of PCP at 60 mg/kg body weight/day, and compared the results with those determined in the Fischer 344 rats (Tables 3 and 4) . For quinone adducts, these predicted steady state levels (values of A 60 ) of total adducts (15.0 and 3.02 nmol/g in liver Cp and Np, respectively) were comparable to those observed in Fischer 344 rats (22.0 and 3.07 nmol/g in liver Cp and Np, respectively). Likewise, for semiquinone adducts the level of Cl 4 -1,2-SQ-Y in liver Cp of Fischer 344 rats (0.463 nmol/g) was comparable to that predicted by the model in the high dose region (0.298 nmol/g) (Table 3) . However, the observed levels of Cl 4 -1,2-SQ-Y in liver Np and Cl 4 -1,4-SQ-Y in liver Cp in Fischer 344 rats were about 16-to 26-fold greater than those predicted by the model. Because it is unlikely that the adduct levels would have been affected by hepatocyte hypertrophy, which was the primary lesion observed in the livers of these rats (NTP, 1997), we suspect that this difference reflects imprecision due to the short half-time for adduct elimination and to measurement of the low levels of adducts. Nevertheless, the good overall agreement of adduct levels between the singleoral dose and chronic-feeding studies of PCP in these two strains of rats suggests that differences in strain and dosing regimen had little impact upon the production of PCP-derived adducts. Additionally, our findings indicate that chronic ingestion of PCP did not result in appreciable accumulation of chlorinated quinoid adducts in rat livers.
If PCP-derived quinones, rather than semiquinones, are responsible for PCP carcinogenicity, then the dosing regimen may have contributed to the negative results in the chronicfeeding studies of PCP in Sprague-Dawley rats (1-30 mg/kg body weight/day, Schwetz et al., 1978) and Fischer 344 rats (10 -60 mg/kg/ body weight/day, NTP, 1997). At these dose levels, bioactivation of PCP in rats favors a less-than-proportional production of quinones, via the indirect oxidation pathway (Fig. 1) . On the other hand, the dose level used in B6C3F 1 mice (17-118 mg/kg body weight) favored the direct oxidation pathway for the formation of PCP quinones. Recent studies of PCP-DNA adducts in the livers of B6C3F 1 mice (15 mg/kg/day for 7 days, Bodell and Pathak, 1998) and in Fischer 344 rats (60 mg/kg/day for 6 months, La et al., 1998) indicated that the relative levels of quinone-derived DNA adducts were 50 fold greater in mice (8 ϫ 10 Ϫ7 ) than in rats (1.5 ϫ 10 Ϫ8 ). This tends Note. Predicted by the model developed for Sprague-Dawley rats at a PCP dose of 60 mg/kg body weight and levels observed in male Fischer 344 rats chronically ingesting 60 mg PCP/kg body weight/day.
a Estimated using Equation 8: A 60 ϭ V 60 /k ae , where A 60 (nmol/g) represents the adduct levels at steady state when the administered doses of PCP is 60 mg/kg body weight/day, V 60 is the rate of adduct production (nmol/g/day) at a PCP dose of 60 mg/kg body weight, and k ae (1/day) is the rate constant representing the initial phase of adduct elimination.
b Not detected.
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to support our speculation that species differences in the dosespecific production of quinones led to the formation of DNA lesions in the livers of mice but not rats. It is worth noting that both Cl 4 -1,2-BQ and Cl 4 -1,4-BQ have been shown to bind covalently to cysteine residues of microtubule proteins, leading to the formation of micronuclei in V79 Chinese hamster lung fibroblasts (Pfeiffer et al., 1996) , and to induce significant increases in the formation of 8-hydroxydeoxyguanosine in V79 Chinese hamster cells (without exogenous metabolic activation) (Dahlhaus et al., 1996) . This suggests that PCP quinones may be responsible for the increase in the formation of 8-hydroxydeoxyguanosine in the livers of male Fischer 344 rats (2-fold increase at PCP doses 60 mg/kg body weight/day for 6 months, La et al., 1998) and in male B6C3F 1 mice (2.8-fold increase at PCP doses 30 -120 mg/kg body weight/day for up to 4 weeks, Umemera et al., 1996) . Given the fact that both Cl 4 -1,2-BQ and Cl 4 -1,4-BQ were present in mouse liver, whereas only Cl 4 -1,4-BQ was detected in the livers of PCP-treated Sprague-Dawley and Fischer 344 rats, we suspect that the type of quinone may also be of importance in PCP carcinogenesis. Taken together, this evidence supports the notion that dose-specific bioactivation of PCP to quinones could well have influenced the production of liver tumors which were observed in B6C3F 1 mice, but not in Sprague-Dawley and Fischer 344 rats, chronically exposed to PCP in long-term feeding studies.
